mSMART, Plasma Cell Proliferative Disorder, FISH, Bone Marrow
Use
The test is useful for detecting recurrent high-risk chromosome abnormalities, such as those associated with multiple myeloma or other plasma cell proliferative disorders, using a laboratory-designated probe set algorithm. It aids in identifying prognostic markers associated with these disorders, which are crucial for selecting appropriate treatment options. Multiple myeloma, often characterized by cytogenetic and molecular heterogeneity, can present varying levels of disease aggressiveness. This test helps in stratifying risk and guiding therapy.
Special Instructions
This test is not directly orderable as it forms part of a broader profile. It is intended to be used adjunctively with existing clinical and pathologic information. The test involves charges for each probe application, analysis, and interpretation performed. Additional charges occur for reflex tests depending on the analysis outcome and available plasma cells.
Limitations
The test is not approved by the FDA and should not replace existing clinical and pathologic evaluation but should complement them. If FISH signals are absent, it indicates a lack of FISH results. Testing depends on the availability of sufficient plasma cells; otherwise, the analysis may be void.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
LOINC Codes
- 93357-2
- 62357-9
- 57802-1
- 69965-2
- 93356-4
- 62356-1
- 42349-1
- 31208-2
- 85298-8
- 85069-3
- 48767-8
- 62364-5
- 18771-6
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
2 mL
Container
Yellow top (ACD), Lavender top (EDTA), or green top (heparin)
Collection Instructions
Only orderable as part of a profile. For more information, see MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow.
Storage Instructions
Ambient (preferred), Refrigerated
Causes for Rejection
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.